Taiwan
· Delayed Price · Currency is TWD AP Biosciences Statistics
Total Valuation
AP Biosciences has a market cap or net worth of TWD 4.17 billion. The enterprise value is 2.50 billion.
| Market Cap | 4.17B |
| Enterprise Value | 2.50B |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AP Biosciences has 84.89 million shares outstanding. The number of shares has increased by 7.45% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 84.89M |
| Shares Change (YoY) | +7.45% |
| Shares Change (QoQ) | +1.30% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 8.89% |
| Float | 50.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 99.21 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.59 |
| EV / Sales | 77.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.87 |
Financial Position
The company has a current ratio of 53.98, with a Debt / Equity ratio of 0.04.
| Current Ratio | 53.98 |
| Quick Ratio | 53.90 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.18 |
| Interest Coverage | -260.21 |
Financial Efficiency
Return on equity (ROE) is -32.20% and return on invested capital (ROIC) is -19.37%.
| Return on Equity (ROE) | -32.20% |
| Return on Assets (ROA) | -19.07% |
| Return on Capital (ROIC) | -19.37% |
| Revenue Per Employee | 871,703 |
| Profits Per Employee | -12.09M |
| Employee Count | 37 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.62% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +15.62% |
| 50-Day Moving Average | 52.44 |
| 200-Day Moving Average | 56.13 |
| Relative Strength Index (RSI) | 35.16 |
| Average Volume (20 Days) | 31,464 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AP Biosciences had revenue of TWD 32.25 million and -447.49 million in losses. Loss per share was -6.87.
| Revenue | 32.25M |
| Gross Profit | 32.25M |
| Operating Income | -455.89M |
| Pretax Income | -447.49M |
| Net Income | -447.49M |
| EBITDA | -443.98M |
| EBIT | -455.89M |
| Loss Per Share | -6.87 |
Balance Sheet
The company has 1.74 billion in cash and 76.52 million in debt, giving a net cash position of 1.66 billion or 19.61 per share.
| Cash & Cash Equivalents | 1.74B |
| Total Debt | 76.52M |
| Net Cash | 1.66B |
| Net Cash Per Share | 19.61 |
| Equity (Book Value) | 1.79B |
| Book Value Per Share | 21.05 |
| Working Capital | 1.74B |
Cash Flow
In the last 12 months, operating cash flow was -399.83 million and capital expenditures -26.36 million, giving a free cash flow of -426.18 million.
| Operating Cash Flow | -399.83M |
| Capital Expenditures | -26.36M |
| Free Cash Flow | -426.18M |
| FCF Per Share | -5.02 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,413.49% |
| Pretax Margin | -1,387.42% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AP Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.45% |
| Shareholder Yield | -7.45% |
| Earnings Yield | -13.98% |
| FCF Yield | -10.23% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AP Biosciences has an Altman Z-Score of 21.24.
| Altman Z-Score | 21.24 |
| Piotroski F-Score | n/a |